Jamie VanHecker

532 total citations
14 papers, 433 citations indexed

About

Jamie VanHecker is a scholar working on Infectious Diseases, Pharmacology and Molecular Medicine. According to data from OpenAlex, Jamie VanHecker has authored 14 papers receiving a total of 433 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Infectious Diseases, 11 papers in Pharmacology and 7 papers in Molecular Medicine. Recurrent topics in Jamie VanHecker's work include Antibiotics Pharmacokinetics and Efficacy (11 papers), Antibiotic Resistance in Bacteria (7 papers) and Antifungal resistance and susceptibility (6 papers). Jamie VanHecker is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (11 papers), Antibiotic Resistance in Bacteria (7 papers) and Antifungal resistance and susceptibility (6 papers). Jamie VanHecker collaborates with scholars based in United States and China. Jamie VanHecker's co-authors include Karen Marchillo, Alexander J. Lepak, David R. Andes, Miao Zhao, Paul G. Ambrose, Daniel J. Diekema, Brian VanScoy, Justin Bader, Hiram Sánchez and Ajit K. Parhi and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy and Open Forum Infectious Diseases.

In The Last Decade

Jamie VanHecker

14 papers receiving 425 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jamie VanHecker United States 12 304 225 171 119 54 14 433
Eleftheria Mavridou Netherlands 11 379 1.2× 310 1.4× 183 1.1× 98 0.8× 94 1.7× 14 551
Laura McEntee United Kingdom 14 502 1.7× 443 2.0× 186 1.1× 96 0.8× 68 1.3× 20 711
Maria Siopi Greece 15 419 1.4× 381 1.7× 94 0.5× 55 0.5× 61 1.1× 56 600
Christine Fregeau United States 8 130 0.4× 119 0.5× 169 1.0× 137 1.2× 24 0.4× 8 315
Andrew P. Davis United States 9 151 0.5× 149 0.7× 105 0.6× 161 1.4× 13 0.2× 17 357
Joanne Livermore United Kingdom 15 579 1.9× 510 2.3× 184 1.1× 63 0.5× 73 1.4× 16 768
Ahmed S. Bueid Saudi Arabia 7 484 1.6× 353 1.6× 57 0.3× 50 0.4× 95 1.8× 8 607
Nicola Farrington United Kingdom 9 151 0.5× 171 0.8× 119 0.7× 90 0.8× 10 0.2× 14 300
Neelam Sachdeva India 7 512 1.7× 419 1.9× 47 0.3× 36 0.3× 27 0.5× 13 599
Sophia Vourli Greece 14 137 0.5× 165 0.7× 129 0.8× 200 1.7× 17 0.3× 28 369

Countries citing papers authored by Jamie VanHecker

Since Specialization
Citations

This map shows the geographic impact of Jamie VanHecker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jamie VanHecker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jamie VanHecker more than expected).

Fields of papers citing papers by Jamie VanHecker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jamie VanHecker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jamie VanHecker. The network helps show where Jamie VanHecker may publish in the future.

Co-authorship network of co-authors of Jamie VanHecker

This figure shows the co-authorship network connecting the top 25 collaborators of Jamie VanHecker. A scholar is included among the top collaborators of Jamie VanHecker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jamie VanHecker. Jamie VanHecker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Zhao, Miao, Alexander J. Lepak, Karen Marchillo, et al.. (2019). APX001 Pharmacokinetic/Pharmacodynamic Target Determination against Aspergillus fumigatus in an In Vivo Model of Invasive Pulmonary Aspergillosis. Antimicrobial Agents and Chemotherapy. 63(4). 34 indexed citations
2.
Lepak, Alexander J., Miao Zhao, Karen Marchillo, Jamie VanHecker, & David R. Andes. (2019). In Vivo Pharmacodynamic Evaluation of Omadacycline against Staphylococcus aureus in the Neutropenic Mouse Pneumonia Model. Antimicrobial Agents and Chemotherapy. 64(2). 11 indexed citations
3.
Lepak, Alexander J., Miao Zhao, Karen Marchillo, Jamie VanHecker, & David R. Andes. (2019). In Vivo Pharmacodynamics of Omadacycline against Staphylococcus aureus in the Neutropenic Murine Thigh Infection Model. Antimicrobial Agents and Chemotherapy. 63(7). 26 indexed citations
4.
Zhao, Miao, Alexander J. Lepak, Brian VanScoy, et al.. (2018). In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model. Antimicrobial Agents and Chemotherapy. 62(4). 54 indexed citations
5.
Zhao, Miao, Alexander J. Lepak, Karen Marchillo, Jamie VanHecker, & David R. Andes. (2018). In Vivo Pharmacodynamic Characterization of a Novel Odilorhabdin Antibiotic, NOSO-502, against Escherichia coli and Klebsiella pneumoniae in a Murine Thigh Infection Model. Antimicrobial Agents and Chemotherapy. 62(9). 12 indexed citations
6.
Lepak, Alexander J., Miao Zhao, Karen Marchillo, Jamie VanHecker, & David R. Andes. (2017). In vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Staphylococcus aureus (SA) in the Murine Thigh Infection Model. Open Forum Infectious Diseases. 4(suppl_1). S478–S479. 3 indexed citations
7.
Lepak, Alexander J., Miao Zhao, Karen Marchillo, Jamie VanHecker, & David R. Andes. (2017). In Vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model. Antimicrobial Agents and Chemotherapy. 61(5). 43 indexed citations
8.
Zhao, Miao, Alexander J. Lepak, Karen Marchillo, Jamie VanHecker, & David R. Andes. (2017). In Vivo Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection Model. Antimicrobial Agents and Chemotherapy. 61(7). 38 indexed citations
9.
Lepak, Alexander J., Karen Marchillo, Jamie VanHecker, Nkechi Azie, & David R. Andes. (2015). Efficacy of Extended-Interval Dosing of Micafungin Evaluated Using a Pharmacokinetic/Pharmacodynamic Study with Humanized Doses in Mice. Antimicrobial Agents and Chemotherapy. 60(1). 674–677. 8 indexed citations
10.
Lepak, Alexander J., et al.. (2015). In Vivo Pharmacodynamic Evaluation of an FtsZ Inhibitor, TXA-709, and Its Active Metabolite, TXA-707, in a Murine Neutropenic Thigh Infection Model. Antimicrobial Agents and Chemotherapy. 59(10). 6568–6574. 21 indexed citations
11.
Lepak, Alexander J., Karen Marchillo, Jamie VanHecker, & David R. Andes. (2015). Impact of Glycopeptide Resistance in Staphylococcus aureus on the Dalbavancin In Vivo Pharmacodynamic Target. Antimicrobial Agents and Chemotherapy. 59(12). 7833–7836. 33 indexed citations
12.
Lepak, Alexander J., Karen Marchillo, Jamie VanHecker, & David R. Andes. (2013). Isavuconazole (BAL4815) Pharmacodynamic Target Determination in an In Vivo Murine Model of Invasive Pulmonary Aspergillosis against Wild-Type and cyp51 Mutant Isolates of Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy. 57(12). 6284–6289. 71 indexed citations
13.
Lepak, Alexander J., Karen Marchillo, Jamie VanHecker, Daniel J. Diekema, & David R. Andes. (2013). Isavuconazole Pharmacodynamic Target Determination for Candida Species in an In Vivo Murine Disseminated Candidiasis Model. Antimicrobial Agents and Chemotherapy. 57(11). 5642–5648. 52 indexed citations
14.
Lepak, Alexander J., Karen Marchillo, Jamie VanHecker, & David R. Andes. (2013). Impact ofIn VivoTriazole and Echinocandin Combination Therapy for Invasive Pulmonary Aspergillosis: Enhanced Efficacy againstCyp51Mutant Isolates. Antimicrobial Agents and Chemotherapy. 57(11). 5438–5447. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eleftheria Mavridou Breakdown of academic impact, for papers by Laura McEntee Breakdown of academic impact, for papers by Maria Siopi Breakdown of academic impact, for papers by Christine Fregeau Breakdown of academic impact, for papers by Andrew P. Davis Breakdown of academic impact, for papers by Joanne Livermore Breakdown of academic impact, for papers by Ahmed S. Bueid Breakdown of academic impact, for papers by Nicola Farrington Breakdown of academic impact, for papers by Neelam Sachdeva Breakdown of academic impact, for papers by Sophia Vourli
Rankless by CCL
2026